Results 151 to 160 of about 13,011 (272)

Long-term hematological response in 5q- syndrome after lenalidomide suspension and further improvement by deferasirox.

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The long-term hematological response in a patient with 5q- syndrome after lenalidomide suspension and the further improvement observe while she was receiving deferasirox alone is reported.
Pasquale Niscola
doaj  

Deferasirox and renal dysfunction in children [PDF]

, 2012
Sunil Bhandari, Shahina Daar
openalex   +1 more source

The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases

, 2019
Manfred Jung, Martin Roatsch, Inga Hoffmann, Martine I. Abboud, Rebecca L. Hancock, Hanna Tarhonskaya, Kuo‐Feng Hsu, Sarah E. Wilkins, Tzu‐Lan Yeh, Kerstin Lippl, Kerstin Serrer, Isabelle Moneke, Theresa D. Ahrens, Dina Robaa, Sandra Wenzler, Henriette Franz, Wolfgang Sippl, Silke Laßmann, Sven Diederichs, Erik Schleicher, Christopher J. Schofield, Akane Kawamura, Roland Schüle   +22 more
openalex   +2 more sources

Deferasirox for managing iron overload in people with thalassaemia [PDF]

, 2017
Claudia Bollig, Lisa Schell, Gerta Rücker, Roman Allert, Edith Motschall, Charlotte M. Niemeyer, Dirk Bassler, Joerg J Meerpohl   +7 more
openalex   +1 more source

Impact of chelator treatment on post-transfusion hemochromatosis in thalassemic patients under Deferasirox

, 2023
Bachir NABTI, Amina BAHLOUL, Djamel BOUKHALFA   +2 more
openalex   +1 more source

Deferasirox nanosuspension loaded dissolving microneedles for ocular drug delivery.

International journal of pharmaceutics
H. Faizi, Muhammad Iqbal Nasiri, Yu Wu, Deepakkumar Mishra, Ryan F. Donnelly, M. Minhas, Lalitkumar K. Vora, Raghu Raj SinghThakur   +7 more
semanticscholar   +1 more source

Therapeutic targeting of the hepcidin-ferroportin axis and erythropoietic modulators: a narrative review. [PDF]

Front Med (Lausanne)
Mansour GK, Hajjar AW, Sajid MR.
europepmc   +1 more source

Iatrogenic iron overload caused by iron isomaltoside treatment: A case report. [PDF]

Medicine (Baltimore)
Hu Y, Sun M, Zhong L, Luo D, Wu Y, Yan Y, Xiang Y.   +6 more
europepmc   +1 more source

METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION OF IMPURITIES IN DEFERASIROX BY RP-HPLC TECHNIQUE

, 2012
Sampath Saravanan, Rama Swetha
openalex   +2 more sources

Clinical-Reported Outcomes Of Deferoxamine Versus Deferasirox In The Treatment Of Homozygous BetaThalassemia

, 2018
Zeina A. Althanoon, Zeina A. Althanoon, Mustafa Basil, Nasih A Al-Kazzaz   +3 more
openalex   +1 more source